MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, ...
– Phase 1 trial to evaluate safety and tolerability of a single ascending dose of RCT1100, an inhaled mRNA-based genetic medicine – First clinical-stage candidate from ReCode’s proprietary SORT LNP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback